Answers are grounded in this paper and cite their sources.
BACKGROUND: Vaccine distribution in low- and middle-income countries is constrained by healthcare workforce shortages - averaging one health worker per 435 people - and by unreliable facility infrastructure. Dissolving microneedle patches address these bottlenecks by reducing cold-chain reliance and enabling dose-sparing immunization through skin-resident antigen-presenting cells. However, reproducible administration by minimally trained personnel remains a critical barrier to deployment. AREA COVERED: This review examines five representative applicator architectures from the peer-reviewed and patent literature, detailing how each converts variable user input into a standardized, high-velocity impact that overcomes rate-dependent skin viscoelasticity to ensure deep, reproducible stratum corneum penetration. Each is evaluated against three prerequisites for global deployment: sufficient insertion force and rate, low-cost manufacturability, and power independence. PubMed, Scopus, Web of Science, and Google Patents were searched from 2004 to June 2026. EXPERT OPINION: Validation remains weighted toward mechanical and ex vivo testing, so the field's engineering maturity runs ahead of its translational readiness. Realizing the public health potential of microneedle vaccines will require user-independent operation, scalable manufacturing, and integration of threshold-triggered mechanisms with patch design so that delivered dose and immune response are reproducible. Eliminating pre-loaded energy components is central to the cost competitiveness that mass immunization in resource-limited settings demands.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: